We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+32.87%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$435M
AUM Growth
+$90.3M
Cap. Flow
+$69M
Cap. Flow %
15.87%
Top 10 Hldgs %
46.41%
Holding
58
New
21
Increased
13
Reduced
6
Closed
12

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$16.9M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$15.1M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.7M
4
PTCT icon
PTC Therapeutics
PTCT
+$14M
5
PRTA icon
Prothena Corp
PRTA
+$11.3M

Top Sells

Rank Stock Value
1
KERX
Keryx Biopharmaceuticals Inc
KERX
+$22M
2
CELG
Celgene Corp
CELG
+$20.3M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$15.5M
4
BMY icon
Bristol-Myers Squibb
BMY
+$14.4M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 70.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
26
Acadia Pharmaceuticals
ACAD
$4.65B
$7.3M 1.68%
300,000
-500,000
-63% -$12.6M
CMRX
27
DELISTED
Chimerix, Inc.
CMRX
$6.85M 1.58%
300,000
+157,000
+110% +$3.17M
OMER icon
28
Omeros
OMER
$937M
$6.04M 1.39%
+500,000
New +$6.14M
GALT icon
29
Galectin Therapeutics
GALT
$196M
$5.33M 1.23%
+348,000
New +$4.96M
PTLA
30
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$5.18M 1.19%
200,000
+125,000
+167% +$3.34M
EGRX
31
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$5.1M 1.17%
+400,000
New +$5.43M
RMTI icon
32
Rockwell Medical
RMTI
$29.9M
$5.06M 1.16%
+3,636
New +$4.73M
NVAX icon
33
Novavax
NVAX
$1.26B
$4.53M 1.04%
50,000
– –
SCTL
34
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$3.66M 0.84%
+557,500
New +$4.05M
GNVC
35
DELISTED
GenVec, Inc.
GNVC
$3.52M 0.81%
+132,930
New +$4.33M
PCRX icon
36
Pacira BioSciences
PCRX
$1.09B
$3.5M 0.8%
50,000
– –
ALNY icon
37
Alnylam Pharmaceuticals
ALNY
$29.3B
$3.36M 0.77%
50,000
-200,000
-80% -$15.5M
AGEN
38
Agenus
AGEN
$346M
$3.17M 0.73%
+50,950
New +$3.54M
NGNE icon
39
Neurogene
NGNE
$686M
$3.14M 0.72%
+12,344
New +$3.17M
GERN icon
40
Geron
GERN
$860M
$3.13M 0.72%
1,587,000
-2,007,191
-56% -$8M
ASPX
41
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$3.08M 0.71%
+100,000
New +$2.69M
BIIB icon
42
Biogen
BIIB
$30.8B
$3.06M 0.7%
+10,000
New +$3.17M
RARE icon
43
Ultragenyx Pharmaceutical
RARE
$2.54B
$2.93M 0.67%
+60,000
New +$3.09M
RGLS
44
DELISTED
Regulus Therapeutics
RGLS
$1.8M 0.41%
1,667
+834
+100% +$924K
ACGN
45
DELISTED
Aceragen Inc
ACGN
$1.63M 0.38%
+2,944
New +$2.01M
AKTX
46
Akari Therapeutics
AKTX
$13.6M
$668K 0.15%
+13
New +$735K
BMY icon
47
Bristol-Myers Squibb
BMY
$135B
– –
-270,000
Closed -$14.4M
ENTA icon
48
Enanta Pharmaceuticals
ENTA
$387M
– –
-10,000
Closed -$273K
PODD icon
49
Insulet
PODD
$11.6B
– –
-150,000
Closed -$5.57M
FPRX
50
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-20,000
Closed -$336K
1
2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2014 Portfolio in Review

As of Q1 2014, Cormorant Asset Management held 58 positions worth $435M, up 26% from $345M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management deployed $69M of net new capital in Q1 2014, opening 21 new positions and adding to 13 existing holdings. Its largest new stake was Intercept Pharmaceuticals, Inc.: 50,000 shares worth $16.5M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 63% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $15.5M trimmed.

  • Cormorant Asset Management's largest Q1 2014 buy was Intercept Pharmaceuticals, Inc.: 50,000 shares worth $16.5M.
  • Cormorant Asset Management added most to BioMarin Pharmaceuticals in Q1 2014, an estimated $14.7M increase.
  • Cormorant Asset Management's biggest Q1 2014 reduction was Alnylam Pharmaceuticals, cutting an estimated $15.5M.
  • Cormorant Asset Management fully exited Keryx Biopharmaceuticals Inc in Q1 2014, selling an estimated $22M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $435M portfolio in Q1 2014.
  • Cormorant Asset Management opened 21 new positions and closed 12 in Q1 2014.
  • Cormorant Asset Management's portfolio value rose 26% quarter-over-quarter to $435M.

Based on Cormorant Asset Management's 13F filing for Q1 2014, filed 15 May 2014.